Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Lung Neoplasms 19Ovarian Neoplasms 15Carcinoma, Non-Small-Cell Lung 14Fallopian Tube Neoplasms 13Colorectal Neoplasms 11Pancreatic Neoplasms 9Carcinoma, Hepatocellular 8Melanoma 6Leukemia, Lymphocytic, Chronic, B-Cell 6Urinary Bladder Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Mycosis Fungoides 5Lymphoma, T-Cell, Cutaneous 5Lymphoma, Large B-Cell, Diffuse 5Prostatic Neoplasms 4Neoplasms 4Neoplasm Metastasis 4Breast Neoplasms 4Triple Negative Breast Neoplasms 3Sezary Syndrome 3Sarcoma 3Rectal Neoplasms 3Myelodysplastic Syndromes 3Multiple Myeloma 3Lymphoma, T-Cell 3Leukemia, Myeloid, Acute 3Glioblastoma 3Colonic Neoplasms 3Cholangiocarcinoma 3Carcinoma, Renal Cell 3

Interventions

Nivolumab 3pembrolizumab 2durvalumab 2tremelimumab 1relatlimab 1lentiviral minigene vaccine of COVID-19 coronavirus 1fludarabine phosphate 1fludarabine 1bintrafusp alfa protein, human 1avelumab 1Therapeutics 1Temozolomide 1Surgical Procedures, Operative 1Specimen Handling 1Oxaliplatin 1Neoadjuvant Therapy 1Ipilimumab 1Injections 1Immunoglobulin G 1High-Throughput Nucleotide Sequencing 1Educational Status 1Drug Therapy 1Disulfides 1Cyclophosphamide 1Chemotherapy, Adjuvant 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Microsatellite Instability × Disulfides × Clear all
NCT02966587 2018-01-17

Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

University of Washington

Phase 2 Withdrawn

Microsatellite Instability

Data powered by HemOnc (CC BY 4.0) Colophon âš¡